Welcome to our dedicated page for AGTC news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on AGTC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AGTC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AGTC's position in the market.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will announce its financial results for Q2 ended December 31, 2021, on February 14, 2022, before market opening. Management will host a conference call at 8:00 AM ET to discuss the results and provide updates on corporate activities.
AGTC focuses on developing gene therapies for rare diseases, notably inherited retinal diseases (IRDs), using adeno-associated virus (AAV) technology. Its ongoing clinical trials target X-linked retinitis pigmentosa and achromatopsia, aiming to meet significant patient needs.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced it exceeded enrollment targets in the SKYLINE trial for its gene therapy AGTC-501, focused on treating X-linked retinitis pigmentosa (XLRP). A total of 14 patients were enrolled, surpassing the goal of 12. The company expects to release interim results by Q2 2022, highlighting visual acuity and mobility data. Key prior findings showed 50% of high-dose patients responded positively after 12 months. The SKYLINE and VISTA trials aim to support registration, pending continued safety data.
Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology firm, announced participation in the H.C. Wainwright Virtual BioConnect Conference from January 10-13, 2022. Sue Washer, President & CEO, and Dr. Susan Schneider, CMO, will hold a fireside chat available on-demand starting January 10, 2022, at 7:00 AM ET. AGTC focuses on AAV-based gene therapies for rare diseases, particularly inherited retinal diseases. The company has active clinical trials targeting conditions like X-linked retinitis pigmentosa and achromatopsia, and is advancing multiple pipeline candidates.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced the appointment of James Robinson to its Board of Directors, enhancing its management team with his extensive experience in biotechnology. Robinson, previously CEO of Urovant Sciences, is expected to contribute significantly to AGTC’s goals in developing gene therapies, particularly for inherited retinal diseases (IRDs). His expertise in commercial operations and organizational leadership is anticipated to bolster AGTC’s pipeline, including late-stage programs for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM).
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced the appointment of Abraham Scaria, Ph.D., as the new Chief Science Officer. With over 25 years of experience in gene therapy and a focus on retinal diseases, Dr. Scaria is expected to enhance AGTC’s clinical and preclinical programs, particularly aimed at treating conditions like X-linked retinitis pigmentosa (XLRP) and achromatopsia. His previous roles include leadership positions at IVERIC Bio and Casebia Therapeutics, where he oversaw significant R&D initiatives.
AGTC presented significant findings regarding AGTC-501, a gene therapy for X-linked retinitis pigmentosa (XLRP) at the AAO 2021 Annual Meeting. The Phase 1/2 trial showed a 50% responder rate after 12 months, with a statistically significant improvement in best-corrected visual acuity (BCVA). No serious adverse events were reported, indicating strong safety and tolerability. The therapy effectively restored the macular ellipsoid zone, supporting its potential as a treatment option for XLRP, a condition with currently no available treatments.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has appointed Hope D'Oyley-Gay as General Counsel, enhancing its leadership team with her extensive experience in legal and business operations within biotech and pharmaceutical sectors. D'Oyley-Gay's past roles include General Counsel at Spirovant Sciences and Vice President at GlaxoSmithKline, where she contributed to strategic collaborations. AGTC is pioneering gene therapies for rare inherited retinal diseases, with ongoing clinical trials and partnerships aimed at advancing its innovative treatment pipeline.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will have its President and CEO, Sue Washer, participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 a.m. ET. This event will focus on the company's advancements in gene therapies for rare inherited retinal diseases. An audio webcast of the presentation will be available here, with a replay accessible on AGTC’s website afterward.
Applied Genetic Technologies Corporation (AGTC) reported a net loss of $17.1 million for Q3 2021, up from $15.4 million in Q3 2020. R&D expenses rose to $12.3 million due to increased spending on XLRP clinical trials. AGTC is optimistic about upcoming milestones, including multiple data readouts for XLRP and ACHM programs in 2022. The company has $90.5 million in cash, expected to support operations into 2023. AGTC has strengthened its leadership team to enhance clinical and regulatory capabilities.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will report its financial results for the quarter ending September 30, 2021, on November 9, 2021, before the market opens. A conference call hosted by AGTC management will commence at 8:00 AM ET to discuss the financial outcomes and provide a corporate update.
AGTC specializes in gene therapies for rare retinal diseases. The company is advancing clinical trials for conditions like X-linked retinitis pigmentosa and achromatopsia, leveraging its technology platform to enhance patient outcomes.
